Search

Your search keyword '"Streb, Joanna"' showing total 202 results
Start Over Author "Streb, Joanna" Publication Year Range Last 50 years
202 results on '"Streb, Joanna"'

1. Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study

Author

Püsküllüoğlu, Miroslawa, Pieniążek, Małgorzata, Las-Jankowska, Manuela, Streb, Joanna, Ziobro, Marek, Pacholczak-Madej, Renata, Kilian-Van Miegem, Paulina, Rudzińska, Agnieszka, Grela-Wojewoda, Aleksandra, Łacko, Aleksandra, Jarząb, Michał, and Polakiewicz-Gilowska, Anna

Published
2024
Full Text
View/download PDF

2. Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism.

Author

Szczepaniak, Piotr, Siedlinski, Mateusz, Hodorowicz-Zaniewska, Diana, Nosalski, Ryszard, Mikolajczyk, Tomasz, Dobosz, Aneta, Dikalova, Anna, Dikalov, Sergey, Streb, Joanna, Gara, Katarzyna, Basta, Pawel, Krolczyk, Jaroslaw, Sulicka-Grodzicka, Joanna, Jozefczuk, Ewelina, Dziewulska, Anna, Saju, Blessy, Laksa, Iwona, Chen, Wei, Dormer, John, Tomaszewski, Maciej, Maffia, Pasquale, Czesnikiewicz-Guzik, Marta, Crea, Filippo, Dobrzyn, Agnieszka, Moslehi, Javid, Grodzicki, Tomasz, Harrison, David, and Guzik, Tomasz

Subjects
Breast cancer, Cardiovascular disease, Molecular biology, Vascular Biology, Animals, Breast Neoplasms, Docetaxel, Endothelial Cells, Endothelium, Vascular, Female, Humans, Hypertension, Mice, NADPH Oxidase 4, NADPH Oxidases, Reactive Oxygen Species
Abstract

Cardiovascular disease is the major cause of morbidity and mortality in breast cancer survivors. Chemotherapy contributes to this risk. We aimed to define the mechanisms of long-term vascular dysfunction caused by neoadjuvant chemotherapy (NACT) and identify novel therapeutic targets. We studied arteries from postmenopausal women who had undergone breast cancer treatment using docetaxel, doxorubicin, and cyclophosphamide (NACT) and from women with no history of such treatment matched for key clinical parameters. We explored mechanisms in WT and Nox4-/- mice and in human microvascular endothelial cells. Endothelium-dependent, NO-mediated vasodilatation was severely impaired in patients after NACT, while endothelium-independent responses remained normal. This was mimicked by a 24-hour exposure of arteries to NACT agents ex vivo. When applied individually, only docetaxel impaired endothelial function in human vessels. Mechanistic studies showed that NACT increased inhibitory eNOS phosphorylation of threonine 495 in a Rho-associated protein kinase-dependent (ROCK-dependent) manner and augmented vascular superoxide and hydrogen peroxide production and NADPH oxidase activity. Docetaxel increased expression of the NADPH oxidase NOX4 in endothelial and smooth muscle cells and NOX2 in the endothelium. A NOX4 increase in human arteries may be mediated epigenetically by diminished DNA methylation of the NOX4 promoter. Docetaxel induced endothelial dysfunction and hypertension in mice, and these were prevented in Nox4-/- mice and by pharmacological inhibition of Nox4 or Rock. Commonly used chemotherapeutic agents and, in particular, docetaxel alter vascular function by promoting the inhibitory phosphorylation of eNOS and enhancing ROS production by NADPH oxidases.

Published
2022

3. Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy.

Author

Duchnowska, Renata, primary, Soter, Katarzyna, additional, Smok-Kalwat, Jolanta, additional, Grela-Wojewoda, Aleksandra, additional, Winsko-Szczęsnowicz, Karolina, additional, Pogoda, Katarzyna, additional, Kade, Grzegorz, additional, Danielewicz, Iwona, additional, Szymanowski, Bartosz, additional, Kiszka, Joanna, additional, Streb, Joanna, additional, Kalinka, Ewa, additional, Łacko, Aleksandra, additional, Żubrowska, Justyna, additional, Ziobro, Marek, additional, Czartoryska-Arlukowicz, Bogumila, additional, Jurczyk, Michał, additional, Lewandowski, Tomasz, additional, Jassem, Jacek, additional, and Bieńkowski, Michał, additional

Published
2024
Full Text
View/download PDF

4. The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0).

Author

Sznurkowski, Jacek J., Bodnar, Lubomir, Szylberg, Łukasz, Zołciak-Siwinska, Agnieszka, Dańska-Bidzińska, Anna, Klasa-Mazurkiewicz, Dagmara, Rychlik, Agnieszka, Kowalik, Artur, Streb, Joanna, Bidziński, Mariusz, and Sawicki, Włodzimierz

Subjects
MINIMALLY invasive procedures, CERVICAL cancer diagnosis, INDUCTION chemotherapy, CERVICAL cancer, TECHNOLOGY assessment
Abstract

Background: Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer. Aim: To summarize the current evidence for the diagnosis, treatment, and follow-up of cervical cancer and provide evidence-based clinical practice recommendations. Methods: Developed according to AGREE II standards, the guidelines classify scientific evidence based on the Agency for Health Technology Assessment and Tariff System criteria. Recommendations are graded by evidence strength and consensus level from the development group. Key Results: (1) Early-Stage Cancer: Stromal invasion and lymphovascular space involvement (LVSI) from pretreatment biopsy identify candidates for surgery, particularly for simple hysterectomy. (2) Surgical Approach: Minimally invasive surgery is not recommended, except for T1A, LVSI-negative tumors, due to a reduction in life expectancy. (3) Locally Advanced Cancer: concurrent chemoradiation (CCRT) followed by brachytherapy (BRT) is the cornerstone treatment. Low-risk patients (fewer than two metastatic nodes or FIGO IB2-II) may consider induction chemotherapy (ICT) followed by CCRT and BRT after 7 days. High-risk patients (two or more metastatic nodes or FIGO IIIA, IIIB, and IVA) benefit from pembrolizumab with CCRT and maintenance therapy. (4) Metastatic, Persistent, and Recurrent Cancer: A PD-L1 status from pretreatment biopsy identifies candidates for Pembrolizumab with available systemic treatment, while triplet therapy (Atezolizumab/Bevacizumab/chemotherapy) becomes a PD-L1-independent option. Conclusions: These evidence-based guidelines aim to improve clinical outcomes through precise treatment strategies based on individual risk factors, predictors, and disease stages. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice

Author

Rutkowski, Piotr, Ziętek, Marcin, Cybulska-Stopa, Bożena, Streb, Joanna, Głuszek, Stanisław, Jankowski, Michał, Łopacka-Szatan, Karolina, Las-Jankowska, Manuela, Hudziec, Piotr, Klimczak, Anna, Olesiński, Tomasz, Świtaj, Tomasz, Koseła-Paterczyk, Hanna, Bylina, Elżbieta, and Osuch, Czesław

Published
2021
Full Text
View/download PDF

8. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial

Author

Cibula, David, Rob, Lukas, Mallmann, Peter, Knapp, Pawel, Klat, Jaroslav, Chovanec, Josef, Minar, Lubos, Melichar, Bohuslav, Hein, Alexander, Kieszko, Dariusz, Pluta, Marek, Spacek, Jiri, Bartos, Pavel, Wimberger, Pauline, Madry, Radoslaw, Markowska, Janina, Streb, Joanna, Valha, Petr, Hassan, Hariz Iskandar Bin, Pecen, Ladislav, Galluzzi, Lorenzo, Fucikova, Jitka, Hrnciarova, Tereza, Hraska, Marek, Bartunkova, Jirina, and Spisek, Radek

Published
2021
Full Text
View/download PDF

9. Encorafenib plus cetuximab in patients with BRAFV600E-mutated metastatic colorectal cancer -- Polish multicenter experience.

Author

Gełej, Marek, Zając, Patryk, Dąbrowska, Maria, Drejws-Wątróbska, Anna, Galińska, Bogumiła, Galus, Łukasz, Gwóźdź-Cieślik, Agnieszka, Hetman, Katarzyna, Kawecki, Maciej, Malik, Mateusz, Streb, Joanna, Wierzbicka, Katarzyna, Wiosek, Piotr, and Radecka, Barbara

Subjects
COLORECTAL cancer, CETUXIMAB, METASTASIS, PROGRESSION-free survival, SURVIVAL rate
Abstract

Introduction. The BRAF mutation occurs in 8-12% of patients with colorectal cancer. This is associated with unfavorable prognosis -- in metastatic disease, median survival does not exceed one year. Molecularly targeted treatment -- encorafenib with cetuximab -- is the standard of care in cases of chemotherapy failure. Material and methods. Medical data of 18 patients treated with encorafenib and cetuximab in 2021-2023 in 10 oncology centers in Poland were assessed. We analyzed clinical, pathomorphological, and molecular factors, as well as the effectiveness and safety of treatment. Results. The median age in the group was 63 years. Patients with metastases limited to one location predominated (78%). Treatment with encorafenib and cetuximab was used not only in the third (in 50% of patients) or fourth (in 28%) lines of treatment but also in the second (in 22%). The objective response rate was 29.4%, and the disease control rate was 76.4%. The median progression-free survival was 7.1 months. Four patients (22%) had a response lasting over 12 months. Conclusions. The results of the analysis confirmed the efficacy and safety of targeted treatment with encorafenib and cetuximab in patients with metastatic colorectal cancer with the BRAFV600E mutation, known from other studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Systemic treatment of patients with advanced pancreatic cancer -- is there still a place for gemcitabine in the first-line setting? Experience of Polish oncology centers.

Author

Raczyński, Ireneusz, Zając, Patryk, Streb, Joanna, Czartoryska-Arłukowicz, Bogumiła, Chruściana-Bołtuć, Aleksandra, Talerczyk, Małgorzata, Wierzbicka, Katarzyna, Siedlaczek, Agnieszka, Radecka, Weronika, Jurczyk, Michał, and Radecka, Barbara

Subjects
PANCREATIC cancer, GEMCITABINE, CANCER prognosis, METASTASIS, PROGRESSION-free survival
Abstract

Introduction. Despite some progress in the treatment of patients with pancreatic cancer, it is still a malignancy with a poor prognosis, which results from its rapid local growth with a tendency to infiltrate surrounding tissues and metastasize, and late diagnosis at the advanced stage. The use of multi-drug regimens and modern targeted therapies did not completely eliminate the use of gemcitabine in monotherapy, which is a therapeutic option mainly in patients with poor performance status, ineligible for more advanced therapies. This study aimed to evaluate the results of treatment with single-agent gemcitabine in everyday clinical practice in Poland and to attempt to identify the predictors of obtaining long-term responses resulting from this treatment. Material and methods. A retrospective analysis of 167 patients with advanced pancreatic cancer treated with single-agent gemcitabine in five oncology centers in Poland in the years 2017-2022 was conducted. Gemcitabine was used as monotherapy at an initial dose of 1000 mg/m2 of body surface area (BSA) weekly, 7 times in an 8-week cycle, then 3 times in a 4-week cycle. Results. Median overall survival (OS) in the entire group of patients was 6.1 months (range -- 0.2-32.3 months), and median progression-free survival (PFS) was 4.2 months (range -- 0.2-31.3 months). A group of 60 patients was identified as "long responders" (LR), with a response of at least 6 months and a group of 107 as "short responders" (SR). Median PFS in the LR group was 9.15 months (range -- 6.0-31.3 months) and in the SR group, it was 3.2 months (range -- 0.2-5.8 months). Median OS was 11.6 months (range -- 5.9-30.8) and 3.8 months (range -- 0.2-32.3 months), respectively. In multivariate analysis, the likelihood of achieving at least a 6-month response (LR) was assessed using a logistic regression model. The model takes into account four variables: the neutrophil/lymphocyte (NLR) ratio, liver metastases, sex, and Hb level. Conclusions. The obtained results confirm that gemcitabine monotherapy is still useful in the first-line treatment of patients with advanced and metastatic pancreatic adenocarcinoma. An appropriate selection of patients for this treatment may improve the results while maintaining lower toxicity compared to combined treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Encorafenib plus cetuximab in patients with BRAFV600E-mutated metastatic colorectal cancer — Polish multicenter experience

Author

Gełej, Marek, primary, Zając, Patryk, additional, Dąbrowska, Maria, additional, Drejws-Wątróbska, Anna, additional, Galińska, Bogumiła, additional, Galus, Łukasz, additional, Gwóźdź-Cieślik, Agnieszka, additional, Hetman, Katarzyna, additional, Kawecki, Maciej, additional, Malik, Mateusz, additional, Streb, Joanna, additional, Wierzbicka, Katarzyna, additional, Wiosek, Piotr, additional, and Radecka, Barbara, additional

Published
2023
Full Text
View/download PDF

12. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus‐based cervical cancer screening with limited genotyping

Author

Trzeszcz, Martyna, primary, Mazurec, Maciej, additional, Jach, Robert, additional, Mazurec, Karolina, additional, Kotkowska‐Szeps, Izabela, additional, Kania, Magdalena, additional, Wantuchowicz, Mariola, additional, Wasowska, Jolanta, additional, Duczek‐Polakiewicz, Monika, additional, Rozmus, Patrycja, additional, Streb, Joanna, additional, and Halon, Agnieszka, additional

Published
2023
Full Text
View/download PDF

13. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Author

Bouzid, Kamel, Campone, Mario, Coudert, Bruno, Nowecki, Zbigniew, Errihani, Hassan, Dalenc, Florence, Ferreira, Ana, Mano, Max, Ricci, Francesco, Kalofonos, Haralabos, Andreetta, Claudia, Montemurro, Filippo, Barrett, Sophie, Zhang, Qingyuan, Mavroudis, Dimitris, Matus, Juan, Beato, Carlos, Hu, Xichun, Gaafar, Rabab, Abdel Azeem, Hamdy, Perrin, Christophe, Ettl, Johannes, Lang, Istvan, Verma, Sunil, Li, Huiping, Brain, Etienne, Hoffmann, Oliver, Cariello, Anna, Tondini, Carlo, Altwegeiri, Taher, Loman, Niklas, Lux, Michael, Frassoldati, Antonio, Aziz, Zeba, Salas, Fernando, Streb, Joanna, Wronski, Andrzej, Menjón Beltrán, Salomón, Cicin, Irfan, Schmid, Peter, Laing, Robert, Tong, Zhongsheng, Boer, Katalin, Juhasz, Balazs, Gianni, Luca, Curigliano, Giuseppe, Juarez, Alejandro, Susnjar, Snezana, Matos, Erika, Uslu, Ruchan, Wildiers, Hans, Cruz, Marcelo, Bourgeois, Hugues, von Schumann, Raquel, Stemmer, Salomón, Vásquez, Flavia Morales, Dominguez, Adriana, Wojtukiewicz, Marek, Trifunovic, Jasna, Illarramendi, Jose Juan, Garcia, Laura, Peron, Yann Izarzugaza, Echarri, Maria Jose, Voitko, Natliia, Wheatley, Duncan, Waters, Simon, De Boer, Richard, Jerusalem, Guy, Cocquyt, Véronique, Barrios, Carlos, Panasci, Lawrence, Mattson, Johanna, Tanner, Minna, Gozy, Michel, Vasilopoulos, Georgios, Revesz, Janos, Latini, Luciano, Gridelli, Cesare, Lazaro, Jesus, Gonzalez, Antonio, Barnadas Molins, Agusti, Martinez, Eduardo, Alarcón, Jesús, Arance, Ana, Klint, Leif, Kovalyov, Oleksiy, Baird, Richard, Yeo, Belinda, McCarthy, Nicole, Greil, Richard, Wang, Shusen, Artignan, Xavier, Augereau, Paule, Juhasz-Boess, Ingolf, Ngan, Roger, Goldberg, Hadassah, Di Costanzo, Francesco, Ferraù, Francesco, Aleknavicius, Eduardas, Rashid, Kamran, Costa, Luís, Angel Garcia, Jose, de la Cruz, Luis Ruiz, López López, Rafael, Del Val, Olga, Ozyilkan, Ozgur, Azribi, Fathi, Verrill, Mark, Turner, Nicholas, Beith, Jane, Petzer, Andreas, Andrade, Jurandyr, Bernstein, Vanessa, Rayson, Daniel, Saad Eldin, Ibtessam, Achille, Mihaëla, Mueller, Volkmar, Gennari, Alessandra, Cascinu, Stefano, Ghosn, Marwan, El-Saghir, Nagi, Van den Bosch, Joan, Oosterkamp, Rianne, Kukulska, Monika, Pelaez, Ignacio, Hernandez, Carolina, del Mar Gordon, Maria, Dalmau, Elsa, Alonso, Jose Luis, Aksoy, Sercan, Coskun, Hasan Senol, Shparyk, Yaroslav, Varughese, Mohini, Panwar, Udaiveer, Barraclough, Lisa, Levitt, Nicola, Hicks, Jonathan, Rigg, Anna, Allen, Mark, Castillo, Cecila, Fein, Luis Enrique, Stuart-Harris, Robin, Singer, Christian, Stoeger, Herbert, Smiljanic, Sasha, Feng, Jifeng, Cedeño, Miguel, Berdah, Jean Francois, Orfeuvre, Hubert, Goncalves, Anthony, Grischke, Eva-Maria, Simon, Eike, Wagner, Steffen, Efremidou, Anna, Papazisis, Konstantinos, Evron, Ella, Inbar, Moshe, Baruch, Noa Ben, Geffen, David, Karminsky, Natalya, Ruggeri, Enzo Maria, Luigi, Cavanna, Grasso, Donatella, Juozaityte, Elona, Rafael Rodriguez Cid, Jeronimo, Roerdink, Henk, Siddiqi, Neelum, Passos Coelho, José Luís, Garre, Elisa Garcia, Garcia, Andres, Martínez Jañez, Noelia, Lopez Ceballos, Maria Helena, Mele, Mireia, García, María, Arcediano, Alberto, McAdam, Karen, Perren, Timothy, Taylor, Wendy, Humphreys, Alison, Vera, Raul, Kaen, Luis Alberto, Steger, Günther, Andel, Johannes, de Grève, Jacques, Huizing, Manon, Hegg, Roberto, Joy, Anil, Sehdev, Sandeep, Kütner, Riina, Ruohola, Johanna, Dohollou, Nadine, Grosjean, Jessica, Laplaige, Philippe, Largillier, Rémy, Martin, Philippe, Pottier, Virginie, Alexandre, Jerome, Christensen, Bernd, Zahm, Dirk-Michael, Khandan, Fariba, Lueck, Hans-Joachim, Fountzilas, Georgios, Fried, Georgeta, Giacobino, Alice, Bonetti, Andrea, Guerra, Yanin Chavarri, Van Warmerdam, Laurens, Van der Velden, Annette, Vrijaldenhoven, Suzan, de Jongh, Felix, Cavero, Milagros, Andres Conejero, Raquel, Murias, Adolfo, Saura, Salvador, Oltra, Amparo, Redondo, Andres, Ribelles, Nuria, Bachmeier, Kilian, Joffe, Johnathan, Chakraborti, Prabir, Beresford, Mark, Butt, Mohammad, Poole, Christopher, Yordi, Gassan, Woodward, Natasha, Amorim, Gilberto, Califaretti, Nadia, Fox, Susan, Robidoux, Andre, Li, NanLi, Li, Nenxiao, Jiang, Jun, Soria, Tannia, Padrik, Peeter, Saarni, Outi, Genet, Dominique, Catala, Stéphanie, Barletta, Hugues, Teixeira, Luis, Facchini, Thomas, Hesse, Tobias, Kühn, Thorsten, Ober, Angelika, Repp, Roland, Schroeder, Willibald, Pectasides, Dimitrios, Bodoky, Gyorgy, Kahan, Zsuzsanna, Jiveliouk, Irina, Rosengarten, Ora, Alabiso, Oscar, Perez, Mario, Van de Wouw, Yes, Smok-Kalwat, Jolanta, Damasceno, Margarida, Sousa, Gabriela, Abulkhair, Omalkhair, Antón Torres, Antonio, Martinez, Maria Purificación, Garcia Mata, Jesús, Jesús Florián Jerico, Marta Santisteban, Llombart, Antonio, Sanchez, Rosa, Torrego, Juan Carlos, Garate, Clara Olier, Rodriguez, Cesar, Llorente, Rosa, de Prado, Diego Soto, Cortés, Javier, Llorca, Cristina, Galán, Antonio, Viñas Villaro, Gemma, Narbe, Ulrik, Bjömeklett, Helena Granstam, Westwell, Sarah, Newby, Jackie, Jafri, Mariam, Rodríguez, Robinson, Alonso, Isabel, Bachelot, T., Ciruelos, E., Schneeweiss, A., Puglisi, F., Peretz-Yablonski, T., Bondarenko, I., Paluch-Shimon, S., Wardley, A., Merot, J.-L., du Toit, Y., Easton, V., Lindegger, N., and Miles, D.

Published
2019
Full Text
View/download PDF

15. Should we use risk selection tests for HPV 16 and/or 18 positive cases: Comparison of p16/Ki67 and cytology.

Author

Mazurec, Karolina, Trzeszcz, Martyna, Mazurec, Maciej, Streb, Joanna, Halon, Agnieszka, and Jach, Robert

Subjects
CERVICAL intraepithelial neoplasia, HUMAN papillomavirus, EARLY detection of cancer, CYTOLOGY, MEDICAL screening, CERVICAL cancer
Abstract

Major screening abnormalities in precolposcopic stage are tests results that imply direct referral to colposcopy (and/or expedited treatment) without performing additional high‐grade squamous intraepithelial lesions or worse (HSIL+) risk selection testing. Currently, both clinically validated HSIL+ risk selection tests, reflex cytology and reflex p16/Ki67 dual staining (DS), are being compared for use in primary human papillomavirus (HPV)‐based screening to avoid possible overtreatment, but there is still no sufficient data available for their performance. Among 30 066 liquid‐based cervical cancer screening tests results, a group of 332 women was selected with available high‐risk types of HPV tests results with 16/18 limited genotyping, liquid‐based cytology, DS, and histology results from standardized colposcopy with biopsy. In HPV 16/18+ cases, three triage approaches were retrospectively analyzed. Predictive values for detection of HSIL+ were calculated and number of colposcopies required in each strategy. Both triage models with DS used (reflex cytology followed by DS, and reflex DS alone in all cases) had significantly higher positive predictive value for HSIL+ than strategy with reflex cytology alone (44.2%/45.7% vs. 28.3%; p < 0.0001). In models with DS, less colposcopies were required (95/92 vs. 152) and less colposcopies were needed per HSIL+ detection (2.26/2.19 vs. 3.54). Only one HSIL+ case was missed in both triage models with DS incorporation. p16/Ki67 dual‐stain may be an effective, alone or combined with cytology, triage test to detect HSIL+ in patients with major screening abnormalities in primary HPV‐based cervical cancer screening. Performing cytology as the first triage test improves the strategy by enabling referrals to expedited treatment in selected cases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Systemic treatment of patients with advanced pancreatic cancer — is there still a place for gemcitabine in the first-line setting? Experience of Polish oncology centers

Author

Raczyński, Ireneusz, primary, Zając, Patryk, additional, Streb, Joanna, additional, Czartoryska-Arłukowicz, Bogumiła, additional, Chruściana-Bołtuć, Aleksandra, additional, Talerczyk, Małgorzata, additional, Wierzbicka, Katarzyna, additional, Siedlaczek, Agnieszka, additional, Radecka, Weronika, additional, Jurczyk, Michał, additional, and Radecka, Barbara, additional

Published
2023
Full Text
View/download PDF

21. Dendritic Cell Subpopulations Are Associated with Prognostic Characteristics of Breast Cancer after Neoadjuvant Chemotherapy—An Observational Study.

Author

Łazarczyk, Agnieszka, Streb, Joanna, Glajcar, Anna, Streb-Smoleń, Anna, Hałubiec, Przemysław, Wcisło, Kacper, Laskowicz, Łukasz, Hodorowicz-Zaniewska, Diana, and Szpor, Joanna

Subjects
*NEOADJUVANT chemotherapy, *DENDRITIC cells, *BREAST, *BREAST cancer, *AXILLA, *TUMOR microenvironment, *SCIENTIFIC observation
Abstract

Breast cancer (BC) is the most prevalent malignancy in women and researchers have strived to develop optimal strategies for its diagnosis and management. Neoadjuvant chemotherapy (NAC), which reduces tumor size, risk of metastasis and patient mortality, often also allows for a de-escalation of breast and axillary surgery. Nonetheless, complete pathological response (pCR) is achieved in no more than 40% of patients who underwent NAC. Dendritic cells (DCs) are professional antigen-presenting cells present in the tumor microenvironment. The multitude of their subtypes was shown to be associated with the pathological and clinical characteristics of BC, but it was not evaluated in BC tissue after NAC. We found that highe r densities of CD123+ plasmacytoid DCs (pDCs) were present in tumors that did not show pCR and had a higher residual cancer burden (RCB) score and class. They were of higher stage and grade and more frequently HER2-negative. The density of CD123+ pCDs was an independent predictor of pCR in the studied group. DC-LAMP+ mature DCs (mDCs) were also related to characteristics of clinical relevance (i.e., pCR, RCB, and nuclear grade), although no clear trends were identified. We conclude that CD123+ pDCs are candidates for a novel biomarker of BC response to NAC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer—A Retrospective Analysis of Consecutive Patients Data

Author

Buda-Nowak, Anna, primary, Kwinta, Łukasz, additional, Potocki, Paweł, additional, Michałowska-Kaczmarczyk, Anna, additional, Słowik, Agnieszka, additional, Konopka, Kamil, additional, Streb, Joanna, additional, Koniewski, Maciej, additional, and Wysocki, Piotr J., additional

Published
2023
Full Text
View/download PDF

28. Breast cancer chemotherapy induces vascular dysfunction and hypertension through NOX4 dependent mechanism

Author

Szczepaniak, Piotr, Siedlinski, Mateusz, Hodorowicz-Zaniewska, Diana, Nosalski, Ryszard, Mikolajczyk, Tomasz P., Dobosz, Aneta M., Dikalova, Anna, Dikalov, Sergey, Streb, Joanna, Gara, Katarzyna, Basta, Pawel, Krolczyk, Jaroslaw, Sulicka-Grodzicka, Joanna, Jozefczuk, Ewelina, Dziewulska, Anna, Saju, Blessy, Laksa, Iwona, Chen, Wei, Dormer, John, Tomaszewski, Maciej, Maffia, Pasquale, Czesnikiewicz-Guzik, Marta, Crea, Filippo, Dobrzyn, Agnieszka, Moslehi, Javid, Grodzicki, Tomasz, Harrison, David G., and Guzik, Tomasz J.

Abstract

Cardiovascular disease is the major cause of morbidity and mortality in breast cancer survivors. Chemotherapy contributes to this risk. We aimed to define the mechanisms of long-term vascular dysfunction caused by neoadjuvant chemotherapy (NACT) and identify novel therapeutic targets.\ud \ud We studied arteries from postmenopausal women who had undergone breast cancer treatment using docetaxel, doxorubicin and cyclophosphamide (NACT), and women with no history of such treatment matched for key clinical parameters. Mechanisms were explored in wild-type and Nox4-/- mice and human microvascular endothelial cells.\ud \ud Endothelium-dependent vasodilatation is severely impaired in patients after NACT, while endothelium-independent responses remain normal. This was mimicked by 24-hour exposure of arteries to NACT agents ex-vivo. When applied individually, only docetaxel impaired endothelial function in human vessels. Mechanistic studies showed that NACT increased inhibitory eNOS phosphorylation of threonine 495 in a ROCK-dependent manner and augmented vascular superoxide and hydrogen peroxide production and NADPH oxidase activity. Docetaxel increased expression of NADPH oxidase NOX4 in endothelial and smooth muscle cells and NOX2 in the endothelium. NOX4 increase in human arteries may be mediated epigenetically by diminished DNA methylation of the NOX4 promoter. Docetaxel induced endothelial dysfunction and hypertension in mice. These were prevented in Nox4-/- and by pharmacological inhibition of Nox4 or Rock.\ud \ud Commonly used chemotherapeutic agents, and in particular, docetaxel, alter vascular function by promoting inhibitory phosphorylation of eNOS and enhancing ROS production by NADPH oxidases.

Published
2022

36. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Author

Vassiliki Karantza, Shparyk Yaroslav, Sumrall Bradley, Javier Cortes, Iwata Hiroji, Kolesnik Oleksii, Ahn Jin Hee, Harbeck Nadia, Prausova Jana, Song Xinni, Berzoy Oleksandr, Mena Raul, Osaki Akihiko, Kahan Zsuzsanna, Simon Michael, Ozguroglu Mustafa, Chmielowska Ewa, Tsugawa Koichiro, Tsao Chao-Jung, Ozyilkan Ozgur, Nowecki Zbigniew, Fadeeva Natalia, Kaen Diego, Garcia Saenz Jose, Porter David, Ngan Kai Cheong Roger, Sherene Loi, Bermejo de las Heras Begona, Turner Nicholas, David W. Cescon, Hope S. Rugo, Oliff Ira, Kelly Catherine, Barrios Carlos, Cole Scott, Shevnya Sergii, Seock-Ah Im, Hoskins Kent, Komisarenko Hanna, Yavuz Sinan, Chaudhry Madhu, Sagara Yasuaki, Brust Leandro, Chan Steve, Gomez Villanueva Angel, Gallardo Carlos, Watanabe Junichiro, Ishikawa Takashi, Schleider Michael, Salas Claudio, Hardy-Bessard Anne-Claire, Erhan Gokmen, Adamchuk Hryhoriy, Beelen Karin, Holeckova Petra, Szczylik Cezary, Fujii Takaaki, Nakamura Seigo, Aruga Tomoyuki, Gokmen Erhan, Jing Zhao, Hiroji Iwata, Molinas Mandel Nil, Gogineni Keerthi, Im Seock-Ah, Zifang Guo, Loi Sherene, Costa Fabiano, Forstmeyer Dirk, Kosaka Yoshimasa, Gomez Diaz Alvaro, Ponomarova Olga, Wimberger Pauline, DAlessio Antonietta, Suzuki Eiji, Blohmer Jens-Uwe, Kowalwszyn Ruben, Molina Matias, Clingan Philip, Yamamoto Yutaka, Sabanathan Dhanusha, Gursel Aktan, Vynnychenko Ihor, Ferrario Cristiano, Schumann Raquel Von, Trukhin Dmytro, Arkosy Peter, Tseng Ling-Ming, Moore Susan, Gunduz Seyda, Stampleman Laura, de Freitas Junior Ruffo, Acevedo Alejandro, Lipatov Oleg, Niikura Naoki, Norikazu Masuda, Rusyn Andrii, Kral Zdenek, Crown John, Yamamoto Naohito, Jakobsen Erik, Blau Sibel, Bustam Anita, Zamora Adelantado Esther, Nanda Rita, Omene Coral, Arslan Cagatay, Kwong Ava, Teixeira Luis, Jensen Jeanette, Ito Yoshinori, Siegel Robert, Mastura Md Yusof, Nowakowska-Zajdel Ewa, Miyoshi Yasuo, Yu Joanne, Tuthill Mark, Mukhametshina Guzel, Matsumoto Koji, Gion Maria, Melichar Bohuslav, Desmoulins Isabelle, Moiseyenko Vladimir, Zurawski Bogdan, Carlos Gallardo, Lorincz Tamas, Cruz Jurado Josefina, Bondarenko Igor, Kaczerowsky Flores de Sousa Anna, Yamauchi Teruo, Loutfi Randa, Esther Holgado, Holgado Esther, Twelves Christopher, Streb Joanna, Tanabe Yuko, Tarnawski Rafal, Morales-Vasquez Flavia, Park Kwong Hwa, Csoszi Tibor, Meshcheryakov Andrey, Scalabrini Neto Antonio Orlando, Oleg Lipatov, Iwasa Tsutomu, Ricevuto Enrico, Tamura Kenji, Patson Brian, Liu Mei-Ching, Cinieri Saverio, Loibl Sibylle, Tjan-Heijnen Vivianne, Glavicic Vesna, Panwalkar Amit, Hargis Jeffrey, Kryzhanivska Anna, Yusof Mastura, O'Reilly Seamus, Rubovszky Gabor, Irvin William, Takahashi Masato, Ohtani Shoichiro, Peter Schmid, Carlos H. Barrios, Sanchez Cesar, Zbigniew Nowecki, Arkhipov Alexander, Chung Michael, Liu Chien-Ting, Mukai Hirofumi, Marco Torregroza Otero, Charpentier Danielle, Park-Simon Tjoung-Won, Lee Keun Seok, Leshchenko Iurii, Huang Chiun-Sheng, Tsai Michaela, Panella Timothy, Petrakova Katarina, MacPherson Iain, Schmid Peter, Baron-Hay Sally, Ursol Grygorii, Lacerda Domicio Carvalho, Cobb Patrick, Sanchez Jesus, Park Yeon Hee, Reyes Contreras Jessica, Fein Luis, Hegg Roberto, Diamond Jennifer, Huober Jens, Rugo Hope, Rybalova Irina, de la Cruz Merino Luis, Linnet Soren, Inoue Kenichi, Wheatley Duncan, Cescon David, Cicin Irfan, Gombos Andrea, Bonnefoi Herve, Nasonova Alla, Taylor Donatienne, Martinez Rodriguez Jorge, Valdes-Albini Frances, Juarez Ramiro Alejandro, Cortes Javier, Lu Janice, Silva Felipe, Lueftner Diana, Landherr Laszlo, Gomez Abuin Gonzalo, Yanez Eduardo, Rocha Roberto Odebrecht, Chow Louis, Otchenash Natalya, Radecka Barbara, Kolesnik Olena, Basaran Gul, Kurbacher Christian, Mahr Karoly, Goncalves Anthony, Begbie Stephen, Graham Janine, Fasching Peter, Varela Mirta, and Lissa Fernando Cezar Toniazzi

Subjects
Oncology, double blind procedure, pharmacist, CD274 protein, human, hazard ratio, 0302 clinical medicine, middle aged, Antineoplastic Combined Chemotherapy Protocols, cancer survival, comparative study, education.field_of_study, progression free survival, adult, drug effect, gemcitabine, clinical trial, General Medicine, nausea, anemia, Progression-Free Survival, priority journal, immunological antineoplastic agent, thyroiditis, pembrolizumab, metastatic breast cancer, neoadjuvant chemotherapy, medicine.medical_specialty, Antineoplastic Agents, intention to treat analysis, Article, skin manifestation, 03 medical and health sciences, Breast cancer, cancer combination chemotherapy, neutropenia, Humans, Progression-free survival, human, education, protein expression, cancer immunotherapy, treatment response, Interim analysis, medicine.disease, major clinical study, tumor recurrence, Carboplatin, programmed death 1 ligand 1, drug efficacy, multicenter study, chemistry, monoclonal antibody, randomized controlled trial, fatigue, drug tolerability, cancer patient, age distribution, drug safety, colitis, clinical outcome, Triple Negative Breast Neoplasms, Pembrolizumab, 030204 cardiovascular system & hematology, B7-H1 Antigen, Placebos, chemistry.chemical_compound, paclitaxel, Antineoplastic Agents, Immunological, Outcome Assessment, Health Care, 030212 general & internal medicine, antineoplastic agent, cancer adjuvant therapy, Eastern Cooperative Oncology Group performance status, female, carboplatin, sodium chloride, immunohistochemistry, medicine.drug, interactive voice response system, alanine aminotransferase, overall survival, Population, Antibodies, Monoclonal, Humanized, Double-Blind Method, Internal medicine, medicine, follow up, hyperthyroidism, pneumonia, controlled study, Taxane, phase 3 clinical trial, business.industry, hypertransaminasemia, alopecia, Gemcitabine, human tissue, cancer recurrence, functional status assessment, triple negative breast cancer, placebo, inoperable cancer, pathology, hypothyroidism, Neoplasm Recurrence, Local, business, metabolism, Follow-Up Studies
Abstract

Background: Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer. Methods: In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer using a block method (block size of six) and an interactive voice-response system with integrated web-response to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo plus chemotherapy. Randomisation was stratified by type of on-study chemotherapy (taxane or gemcitabine–carboplatin), PD-L1 expression at baseline (combined positive score [CPS] ?1 or, Breast Cancer Research Foundation, BCRF; Pfizer; AstraZeneca; Merck; Roche; Samsung; Merck Sharp and Dohme, MSD; Eisai, JC reports personal fees and research funding paid to his institution from Roche, AstraZeneca, Merck Sharp & Dohme, and Eisai; personal fees from Celgene, Cellestia, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, GlaxoSmithKline, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Kyowa Kirin, Novartis, Pfizer, Samsung Bioepis; research funding paid to his institution from Ariad Pharmaceuticals, Bayer Healthcare, F Hoffman-La Roche, Guardanth Health, Piqur Therapeutics, Puma C, and Queen Mary University of London, outside the submitted work. In addition, JC has a MedSIR patent pending. DWC reports research support from Merck during the conduct of the study; research support paid to his institution from Merck, Pfizer, and GlaxoSmithKline; personal fees from Merck, Roche–Genentech, AstraZeneca, GlaxoSmithKline, Novartis, Pfizer, Puma, Agenda, Exact Sciences, and Dynamo Therapeutics, outside the submitted work. In addition, DWC has a Biomarkers of TTK inhibitors patent pending. HSR reports funding for sponsored studies paid to the University of California San Francisco from Pfizer, Novartis, Lilly, Roche–Genentech, Macrogenics, OBI, Merck, Eisai, Immunomedics, Daiichi Sankyo, Seattle Genetics, and Odonate; travel support for educational meetings from Daiichi Sankyo, Mylan, Pfizer, Merck, AstraZeneca, Novartis, and Macrogenics; and consulting fees from Samsung and Puma, outside the submitted work. S-AI reports grants from AstraZeneca, Eisai, Pfizer, Roche, and Daewoong; an advisory role for AstraZeneca, Amgen, Eisai, Hanmi, Novartis, Lily, MedPacto, Pfizer, and Roche; and travel expenses for presentation from Novartis, outside the submitted work. CG reports Advisory Board fees from Merck Sharp & Dohme and Roche; and speaker's bureau fees from Bristol Myers Squibb and AstraZeneca, outside the submitted work. CHB reports grants and fees from Merck Sharp & Dohme for clinical research consulting during the conduct of the study; consulting–advisory role fees from Boehringer Ingelheim, GlaxoSmithKline, and Bayer; consulting–advisory role fees and grants for clinical research from Novartis, Pfizer, Roche–Genentech, Eisai, Merck Sharp & Dohme, and AstraZeneca; grants for clinical research from Abbvie, Amgen, Astellas Pharma, Bristol Myers Squibb, Celgene, Covance, Lilly, Medication, Merck Serono, and PharmaMar; grants for academic research projects from CPO, Pontificia Universidade Católica do Rio Grande do Sul, Latin American Cooperative Oncology Group, Grupo Brasileiro Estudos Câncer Mama, and Instituto Nacional de Câncer-Brazil, outside the submitted work. HI reports a grant from Merck Sharp & Dohme during the conduct of the study; honoraria and consulting fees from Novartis, AstraZeneca, Pfizer, Lilly, Daiichi Sankyo, Eisai, and Chugai; and a grant from Chugai, outside the submitted work. NM reports honoraria and research funding paid to his institution from Chugai, AstraZeneca, Pfizer, Eli-Lilly, Eisai, Takeda, Kyowa-Kirin, Merck Sharp & Dohme, Novartis, and Daiichi Sankyo, outside the submitted work. EG reports non-financial support from Merck Sharp & Dohme during the conduct of the study; honoraria, consulting–advisory fees and meeting support from Novartis, Roche, Bristol Myers Squibb, and Pfizer; and honoraria from AstraZeneca and Astellas, outside the submitted work. SL reports research funding or consulting fees paid to her institution from Bristol Myers Squibb, Roche–Genentech, Puma Biotechnology, Pfizer, Seattle Genetics, Novartis, Merck Sharp & Dohme, Eli Lilly, Aduro Biotech, GI Therapeutics, AstraZeneca, and GlaxoSmithKline; and non-remunerated consultancy for Bristol Myers Squibb, Roche–Genentech, Pfizer, Seattle Genetics, Novartis, Merck Sharp & Dohme, and AstraZeneca, outside the submitted work. In addition, SL is supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York. ZG, JZ, GA, and VK are employees of Merck Sharp & Dohme and own stock or stock options in Merck. PS reports consultancy fees from Pfizer, AstraZeneca, Novartis, Roche, Merck Sharp & Dohme, Boehringer Ingelheim, Bayer, Eisai, Celgene, and Puma; consultancy fees to his spouse from Genentech and Roche; and grants or funding to his institution from Roche, Genentech, Oncogenex, Novartis, Astellas, and AstraZeneca, outside the submitted work. All other authors declare no competing interests., The authors thank the patients, their families and caregivers for participating in this trial, all of the investigators and site personnel, and the following employees of Merck Sharp & Dohme: Wilbur Pan, Deborah Card, Eleanor Readinger, Shana Hamm, Roger Maxwell, and Krystal Bourdon, for collection of data, supervision of research, provision of study materials or patients or administrative or logistical support; Aline Galvao, for collection of data, supervision of research, administrative or logistical support, and review of imaging data related to the primary end point; Donna Letizia, for collection of data and imaging expertise; Jennifer Kimmel, for study management; Mercedes Bustamante, for data collection and management; Xuan Zhou and Madhusudhan Reddy Papasani, for statistical expertise; Christine McCrary Sisk, for medical writing and editorial assistance; and Joseph C Naggar and Michele McColgan, for administrative or logistical support.

Published
2020

37. Discrepancies in breast cancer management

Author

Seweryn, Michał, primary, Banaś, Tomasz, additional, Streb, Joanna, additional, Matkowski, Rafał, additional, Wysocki, Wojciech, additional, Augustyńska, Joanna, additional, Kopel, Justyna, additional, and Kizińska, Ola, additional

Published
2021
Full Text
View/download PDF

38. Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland

Author

Kufel-Grabowska, Joanna, primary, Radecka, Barbara, additional, Streb, Joanna, additional, Jagiełło-Gruszfeld, Agnieszka, additional, Hudała-Klecha, Joanna, additional, Szombara, Ewa, additional, Sienkiewicz, Renata, additional, Czartoryska-Arłukowicz, Bogumiła, additional, Witasik, Piotr, additional, Sokołowska, Katarzyna, additional, and Wysocki, Wojciech, additional

Published
2020
Full Text
View/download PDF

39. Expression of Vascular Endothelial Growth Factors VEGF- C and D, VEGFR-3, and Comparison of Lymphatic Vessels Density Labeled with D2-40 Antibodies as a Prognostic Factors in Vulvar Intraepithelial Neoplasia (VIN) and Invasive Vulvar Cancer

Author

Jach, Robert, primary, Dyduch, Grzegorz, additional, Rado-Pokracka, Magorzata, additional, Przybylska, Paulina, additional, Mika, Marcin, additional, Stangel-Wojcikiewicz, Klaudia, additional, Duliska-Litewka, Joanna, additional, Zajc, Krzysztof, additional, Huras, Hubert, additional, Streb, Joanna, additional, and Dziadek, Olivia, additional

Published
2012
Full Text
View/download PDF

40. Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience.

Author

Püsküllüoğlu, Mirosława, Swiderska, Katarzyna, Konieczna, Aleksandra, Streb, Joanna, Grela-Wojewoda, Aleksandra, Rudzinska, Agnieszka, Dobrzańska, Jolanta, Pacholczak-Madej, Renata, Mucha-Malecka, Anna, Kunkiel, Michał, Mitus, Jerzy W., Jarząb, Michał, and Ziobro, Marek

Subjects
EPIDERMAL growth factor receptors, PROGNOSIS, PALLIATIVE treatment
Abstract

Metaplastic breast cancer (BC-Mp), which includes a range of epithelial and mixed epithelial-mesenchymal tumours, are rare malignancies with an unfavourable prognosis. The limited literature on BC-Mp focuses mainly on retrospective data for radically treated patients. Notably absent are studies dedicated to the palliative treatment of BC-Mp with distant metastases. The present retrospective study investigated treatment modalities and prognosis in a multi-centre cohort of 31 female participants diagnosed with distant metastatic BC-Mp, including 7 patients with de novo metastatic disease. The median age of the patients was 61 years (range, 33–87 years), with 38.7% presenting local lymph node involvement. Lungs were the most common site for the metastatic disease (61.3%). Median Ki-67 index was 50% (range, 35–70%), and 80.7% of cases were classified as grade 3. Human epidermal growth factor receptor 2 (HER2)+ and estrogen receptor+ were detected in 12.9 and 6.5% of cases, respectively. A total of 62.4% of patients received first-line palliative systemic treatment. The 1- and 2-year overall survival (OS) were 38.5 and 19.2%, respectively. Receiving ≥1 line of palliative treatment was significantly associated with improved OS (P<0.001). Factors such as age, Ki-67 index, HER2 or hormonal status, presence of specific epithelial or mesenchymal components, location of metastases or chemotherapy regimen type did not influence OS. The present study provided insights into the clinicopathological profile, systemic treatment experience, prognostic factors and OS data of BC-Mp with distant metastases, emphasizing the imperative for clinical trials in this population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. The real world outcomes of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST).

Author

Rutkowski, Piotr, primary, Zietek, Marcin, additional, Cybulska-Stopa, Bozena, additional, Streb, Joanna, additional, Gluszek, Stanislaw, additional, Jankowski, Michał, additional, Lopacka-Szatan, Karolina, additional, Las-Jankowska, Manuela, additional, Hudziec, Piotr, additional, Klimczak, Anna, additional, Olesinski, Tomasz, additional, Switaj, Tomasz, additional, Kosela-Paterczyk, Hanna, additional, Bylina, Elzbieta, additional, and Osuch, Czeslaw, additional

Published
2020
Full Text
View/download PDF

42. Systemic treatment of patients with solid tumors during the COVID-19 (SARS-CoV-2) pandemic — comprehensive recommendations of the Polish Society of Clinical Oncology

Author

Wysocki, Piotr J, primary, Kwinta, Łukasz, additional, Potocki, Paweł, additional, Konopka, Kamil, additional, Streb, Joanna, additional, Wojtukiewicz, Marek Z, additional, Radecka, Barbara, additional, Tomczak, Piotr, additional, Jarząb, Michał, additional, Kawecki, Andrzej, additional, and Krzakowski, Maciej, additional

Published
2020
Full Text
View/download PDF

44. Związek leczenia chirurgicznego (mastektomia vs. zabieg oszczędzający pierś) z akceptacją cielesności, eksponowaniem kobiecości i przeżywaniem intymnej relacji z partnerem w grupie kobiet z rakiem piersi

Author

Jabłoński, Marcin J., Streb, Joanna, Mirucka, Beata, Słowik, Agnieszka J., and Jach, Robert

Subjects
rak piersi, breast cancer, Ja cielesne, mastektomia, mastectomy, self-acceptance, body self, samoakceptacja
Abstract

Aim. The aim of the study was to verify the following hypotheses: (1) Do women who have undergone surgical treatment for breast cancer differ from healthy women in the way they experience their body (body self)?; (2) Does the surgical technique (mastectomy vs. breast conserving treatment) differentiate the group in terms of experiencing their body after the surgery?; (3) Do demographic variables, BMI, breast size and the evaluation of the scar differentiate the group in terms of experiencing their body self after the surgery? Method. In order to gain some insight into how women experience their body after breast surgery, the Body Self Questionnaire designed in 2005 by Beata Mirucka was used. The analysis included data from 50 women who completed surveys. This data were compared to the control group. Data were analyzed using IBM SPSS Statistics package, version 24, with a one-way analysis of variance (ANOVA). Results. Statistically significant differences were obtained between the entire group of women after breast surgery (mastectomy and BCT, jointly) and the control group of healthy women in three aspects of the Body Self Questionnaire: body acceptance, manifesting femininity and experiencing an intimate relation with a partner. Conclusions. Surgical treatment of breast cancer is significantly associated with the way patients experience their body, which is expressed in three dimensions of the body self in treated women.

Published
2018

45. Prognostic value of the pretreatment neutrophil‑to‑lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure

Author

Sobczuk, Paweł, primary, Teterycz, Paweł, additional, Lugowska, Iwona, additional, Klimczak, Anna, additional, Bylina, Elżbieta, additional, Czarnecka, Anna, additional, Kosela‑Paterczyk, Hanna, additional, Osuch, Czesław, additional, Streb, Joanna, additional, and Rutkowski, Piotr, additional

Published
2019
Full Text
View/download PDF

47. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Author

Bachelot, T., primary, Ciruelos, E., additional, Schneeweiss, A., additional, Puglisi, F., additional, Peretz-Yablonski, T., additional, Bondarenko, I., additional, Paluch-Shimon, S., additional, Wardley, A., additional, Merot, J.-L., additional, du Toit, Y., additional, Easton, V., additional, Lindegger, N., additional, Miles, D., additional, Bouzid, Kamel, additional, Campone, Mario, additional, Coudert, Bruno, additional, Nowecki, Zbigniew, additional, Errihani, Hassan, additional, Dalenc, Florence, additional, Ferreira, Ana, additional, Mano, Max, additional, Ricci, Francesco, additional, Kalofonos, Haralabos, additional, Andreetta, Claudia, additional, Montemurro, Filippo, additional, Barrett, Sophie, additional, Zhang, Qingyuan, additional, Mavroudis, Dimitris, additional, Matus, Juan, additional, Beato, Carlos, additional, Hu, Xichun, additional, Gaafar, Rabab, additional, Abdel Azeem, Hamdy, additional, Perrin, Christophe, additional, Ettl, Johannes, additional, Lang, Istvan, additional, Verma, Sunil, additional, Li, Huiping, additional, Brain, Etienne, additional, Hoffmann, Oliver, additional, Cariello, Anna, additional, Tondini, Carlo, additional, Altwegeiri, Taher, additional, Loman, Niklas, additional, Lux, Michael, additional, Frassoldati, Antonio, additional, Aziz, Zeba, additional, Salas, Fernando, additional, Streb, Joanna, additional, Wronski, Andrzej, additional, Menjón Beltrán, Salomón, additional, Cicin, Irfan, additional, Schmid, Peter, additional, Laing, Robert, additional, Tong, Zhongsheng, additional, Boer, Katalin, additional, Juhasz, Balazs, additional, Gianni, Luca, additional, Curigliano, Giuseppe, additional, Juarez, Alejandro, additional, Susnjar, Snezana, additional, Matos, Erika, additional, Uslu, Ruchan, additional, Wildiers, Hans, additional, Cruz, Marcelo, additional, Bourgeois, Hugues, additional, von Schumann, Raquel, additional, Stemmer, Salomón, additional, Vásquez, Flavia Morales, additional, Dominguez, Adriana, additional, Wojtukiewicz, Marek, additional, Trifunovic, Jasna, additional, Illarramendi, Jose Juan, additional, Garcia, Laura, additional, Peron, Yann Izarzugaza, additional, Echarri, Maria Jose, additional, Voitko, Natliia, additional, Wheatley, Duncan, additional, Waters, Simon, additional, De Boer, Richard, additional, Jerusalem, Guy, additional, Cocquyt, Véronique, additional, Barrios, Carlos, additional, Panasci, Lawrence, additional, Mattson, Johanna, additional, Tanner, Minna, additional, Gozy, Michel, additional, Vasilopoulos, Georgios, additional, Revesz, Janos, additional, Latini, Luciano, additional, Gridelli, Cesare, additional, Lazaro, Jesus, additional, Gonzalez, Antonio, additional, Barnadas Molins, Agusti, additional, Martinez, Eduardo, additional, Alarcón, Jesús, additional, Arance, Ana, additional, Klint, Leif, additional, Kovalyov, Oleksiy, additional, Baird, Richard, additional, Yeo, Belinda, additional, McCarthy, Nicole, additional, Greil, Richard, additional, Wang, Shusen, additional, Artignan, Xavier, additional, Augereau, Paule, additional, Juhasz-Boess, Ingolf, additional, Ngan, Roger, additional, Goldberg, Hadassah, additional, Di Costanzo, Francesco, additional, Ferraù, Francesco, additional, Aleknavicius, Eduardas, additional, Rashid, Kamran, additional, Costa, Luís, additional, Angel Garcia, Jose, additional, de la Cruz, Luis Ruiz, additional, López López, Rafael, additional, Del Val, Olga, additional, Ozyilkan, Ozgur, additional, Azribi, Fathi, additional, Verrill, Mark, additional, Turner, Nicholas, additional, Beith, Jane, additional, Petzer, Andreas, additional, Andrade, Jurandyr, additional, Bernstein, Vanessa, additional, Rayson, Daniel, additional, Saad Eldin, Ibtessam, additional, Achille, Mihaëla, additional, Mueller, Volkmar, additional, Gennari, Alessandra, additional, Cascinu, Stefano, additional, Ghosn, Marwan, additional, El-Saghir, Nagi, additional, Van den Bosch, Joan, additional, Oosterkamp, Rianne, additional, Kukulska, Monika, additional, Pelaez, Ignacio, additional, Hernandez, Carolina, additional, del Mar Gordon, Maria, additional, Dalmau, Elsa, additional, Alonso, Jose Luis, additional, Aksoy, Sercan, additional, Coskun, Hasan Senol, additional, Shparyk, Yaroslav, additional, Varughese, Mohini, additional, Panwar, Udaiveer, additional, Barraclough, Lisa, additional, Levitt, Nicola, additional, Hicks, Jonathan, additional, Rigg, Anna, additional, Allen, Mark, additional, Castillo, Cecila, additional, Fein, Luis Enrique, additional, Stuart-Harris, Robin, additional, Singer, Christian, additional, Stoeger, Herbert, additional, Smiljanic, Sasha, additional, Feng, Jifeng, additional, Cedeño, Miguel, additional, Berdah, Jean Francois, additional, Orfeuvre, Hubert, additional, Goncalves, Anthony, additional, Grischke, Eva-Maria, additional, Simon, Eike, additional, Wagner, Steffen, additional, Efremidou, Anna, additional, Papazisis, Konstantinos, additional, Evron, Ella, additional, Inbar, Moshe, additional, Baruch, Noa Ben, additional, Geffen, David, additional, Karminsky, Natalya, additional, Ruggeri, Enzo Maria, additional, Luigi, Cavanna, additional, Grasso, Donatella, additional, Juozaityte, Elona, additional, Rafael Rodriguez Cid, Jeronimo, additional, Roerdink, Henk, additional, Siddiqi, Neelum, additional, Passos Coelho, José Luís, additional, Garre, Elisa Garcia, additional, Garcia, Andres, additional, Martínez Jañez, Noelia, additional, Lopez Ceballos, Maria Helena, additional, Mele, Mireia, additional, García, María, additional, Arcediano, Alberto, additional, McAdam, Karen, additional, Perren, Timothy, additional, Taylor, Wendy, additional, Humphreys, Alison, additional, Vera, Raul, additional, Kaen, Luis Alberto, additional, Steger, Günther, additional, Andel, Johannes, additional, de Grève, Jacques, additional, Huizing, Manon, additional, Hegg, Roberto, additional, Joy, Anil, additional, Sehdev, Sandeep, additional, Kütner, Riina, additional, Ruohola, Johanna, additional, Dohollou, Nadine, additional, Grosjean, Jessica, additional, Laplaige, Philippe, additional, Largillier, Rémy, additional, Martin, Philippe, additional, Pottier, Virginie, additional, Alexandre, Jerome, additional, Christensen, Bernd, additional, Zahm, Dirk-Michael, additional, Khandan, Fariba, additional, Lueck, Hans-Joachim, additional, Fountzilas, Georgios, additional, Fried, Georgeta, additional, Giacobino, Alice, additional, Bonetti, Andrea, additional, Guerra, Yanin Chavarri, additional, Van Warmerdam, Laurens, additional, Van der Velden, Annette, additional, Vrijaldenhoven, Suzan, additional, de Jongh, Felix, additional, Cavero, Milagros, additional, Andres Conejero, Raquel, additional, Murias, Adolfo, additional, Saura, Salvador, additional, Oltra, Amparo, additional, Redondo, Andres, additional, Ribelles, Nuria, additional, Bachmeier, Kilian, additional, Joffe, Johnathan, additional, Chakraborti, Prabir, additional, Beresford, Mark, additional, Butt, Mohammad, additional, Poole, Christopher, additional, Yordi, Gassan, additional, Woodward, Natasha, additional, Amorim, Gilberto, additional, Califaretti, Nadia, additional, Fox, Susan, additional, Robidoux, Andre, additional, Li, NanLi, additional, Li, Nenxiao, additional, Jiang, Jun, additional, Soria, Tannia, additional, Padrik, Peeter, additional, Saarni, Outi, additional, Genet, Dominique, additional, Catala, Stéphanie, additional, Barletta, Hugues, additional, Teixeira, Luis, additional, Facchini, Thomas, additional, Hesse, Tobias, additional, Kühn, Thorsten, additional, Ober, Angelika, additional, Repp, Roland, additional, Schroeder, Willibald, additional, Pectasides, Dimitrios, additional, Bodoky, Gyorgy, additional, Kahan, Zsuzsanna, additional, Jiveliouk, Irina, additional, Rosengarten, Ora, additional, Alabiso, Oscar, additional, Perez, Mario, additional, Van de Wouw, Yes, additional, Smok-Kalwat, Jolanta, additional, Damasceno, Margarida, additional, Sousa, Gabriela, additional, Abulkhair, Omalkhair, additional, Antón Torres, Antonio, additional, Martinez, Maria Purificación, additional, Garcia Mata, Jesús, additional, Jesús Florián Jerico, Marta Santisteban, additional, Llombart, Antonio, additional, Sanchez, Rosa, additional, Torrego, Juan Carlos, additional, Garate, Clara Olier, additional, Rodriguez, Cesar, additional, Llorente, Rosa, additional, de Prado, Diego Soto, additional, Cortés, Javier, additional, Llorca, Cristina, additional, Galán, Antonio, additional, Viñas Villaro, Gemma, additional, Narbe, Ulrik, additional, Bjömeklett, Helena Granstam, additional, Westwell, Sarah, additional, Newby, Jackie, additional, Jafri, Mariam, additional, Rodríguez, Robinson, additional, and Alonso, Isabel, additional

Published
2019
Full Text
View/download PDF

48. Bowel or ovarian cancer? Ambiguous diagnosis and non-standard treatment with good outcomes. A case report

Author

Cybulska-Stopa, Bożena, Koper, Krzysztof, Streb, Joanna, and J. Wysocki, Piotr

Subjects
ovarian cancer, HIPEC, interdisciplinary therapy, small bowel cancer
Abstract

The treatment of patients with cancer has recently become more complex and challenging for oncologists. The paper presents a case of a 54-year-old woman treated due to small bowel adenocarcinoma, who underwent primary surgical procedure and adjuvant therapy, and who developed intra-abdominal cancer dissemination. Initially, XELOX regimen was administered, followed by multiorgan resection performed by an interdisciplinary team of gynecologists and surgeons as well as hyperthermic intraperitoneal chemotherapy (HIPEC). The therapy was complicated by impaired wound healing and an enterocutaneous fistula. Currently, the patient is under a follow-up and shows no evidence of recurrence. The wounds after the surgery and fistulas are healed, normal gastrointestinal function is preserved.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results